Innate Pharma

Report Publication Announcement • Sep 14, 2011

INNATE PHARMA TO PRESENT AT TWO UPCOMING INVESTOR CONFERENCES

Marseilles, France, September 14, 2011

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces that it will participate in the following investor conferences in the coming weeks:

• Paris Midcap Event, Palais Brongniard, Paris, on September 22 & 23, 2011;
• BioInvestor Forum, Palace Hotel, San Francisco, on October 25 & 26, 2011. During this event, Hervé Brailly, CEO of Innate Pharma, will participate in a panel on Cancer Immunotherapy (Immunotherapy: Heal Thyself, Tuesday, October 25th, 10:30am-11:25am, Twin Peaks N/S).

Innate Pharma is committed to meet on a regular basis with the financial community. Investors can also find updated information on the company's website (www.innatepharma.com) and contact the investor relations team by writing to investors@innatepharma.com.

-Ends-

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approach has been validated by licence agreements with two major pharmaceutical companies, Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in Marseilles, France, and had 78 employees as at June 30, 2011.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Laure-Hélène Mercier Director, Investor Relations Phone: +33 (0)4 30 30 30 87 Mob.: +33 (0)6 26 94 18 53 Phone: +44 (0)20 7920 2330 investors@innate-pharma.com mb@atcg-partners.com innatepharma@mcomgroup.com

Innate Pharma French enquiries ATCG Press

Marielle Bricman Phone: +33 (0)4 91 25 07 85

International enquiries M:Communications

Peter Laing, Amber Bielecka